| Followers | 30 |
| Posts | 3322 |
| Boards Moderated | 0 |
| Alias Born | 08/21/2015 |
Saturday, September 18, 2021 2:02:13 PM
I don’t think you or others realize what this paragraph means.
“Due to the fact that Paul Rosenbaum, Jeffrey Beaty and Art Wilmes have separately decided to undertake to nominate a slate of directors for election at the Annual Meeting, the Reporting Persons have terminated their agreement as to the purposes stated in the Schedule 13D. As a result, the Reporting Persons are not acting in concert for 13D purposes and, therefore, are no longer part of a group. Accordingly, this Amendment No. 3 constitutes an exit filing for all of the Reporting Persons.”
The slate of directors has been nominated for election at the annual meeting following settlement of the lawsuit yesterday. The 13d is no longer needed since this occurred and that’s what this paragraph is outlining (exit filing of the reporting persons of the 13d). The vote appears to be moving forward as long as the court clears it on October 6th, which may not even be needed if the parties settled this lawsuit.
Bottom line: CYDY knew from the beginning that they couldn’t stop a vote. They attempted to slow it by checking how deep the pockets of the 13d were (by filing a lawsuit) and the 13d’s pockets were deep enough to call CYDY’s bluff. CYDY appears to have offered settlement terms and the 13d agreed. The vote will likely take place and will know soon enough who controls the company.
“Due to the fact that Paul Rosenbaum, Jeffrey Beaty and Art Wilmes have separately decided to undertake to nominate a slate of directors for election at the Annual Meeting, the Reporting Persons have terminated their agreement as to the purposes stated in the Schedule 13D. As a result, the Reporting Persons are not acting in concert for 13D purposes and, therefore, are no longer part of a group. Accordingly, this Amendment No. 3 constitutes an exit filing for all of the Reporting Persons.”
The slate of directors has been nominated for election at the annual meeting following settlement of the lawsuit yesterday. The 13d is no longer needed since this occurred and that’s what this paragraph is outlining (exit filing of the reporting persons of the 13d). The vote appears to be moving forward as long as the court clears it on October 6th, which may not even be needed if the parties settled this lawsuit.
Bottom line: CYDY knew from the beginning that they couldn’t stop a vote. They attempted to slow it by checking how deep the pockets of the 13d were (by filing a lawsuit) and the 13d’s pockets were deep enough to call CYDY’s bluff. CYDY appears to have offered settlement terms and the 13d agreed. The vote will likely take place and will know soon enough who controls the company.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
